Join Now

Utah Life Sciences News & Events

PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

January 19, 2022

PolarityTE, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for the evaluation of SkinTE for the treatment of chronic cutaneous ulcers. This follows the Company satisfactorily addressing clinical hold items that the FDA had previously identified.  The approval enables PolarityTE to commence the first of two expected pivotal studies needed to support a biologics license application (BLA) seeking a chronic cutaneous ulcer indication for SkinTE.

Richard Hague, Chief Executive Officer and President of PolarityTE, commented, “The clearance of our IND is a critical milestone for PolarityTE and a testament to the talent and hard work of our entire team.  It is important to note that our strategy to pursue a complex chronic cutaneous ulcer indication, which includes the most challenging and cost-intensive wounds, is based on the learnings from our prior commercial experience as a 361 HCT/P and from our previous non-IND DFU and VLU RCTs, which gives us a great deal of confidence as we look forward to commencing our first pivotal study in the very near future.”

The first planned pivotal study is a multi-center, randomized controlled trial evaluating SkinTE in the treatment of Wager 2 DFUs entitled “Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE,” or “COVER DFUs.”  The Company plans to enroll up to 100 patients at up to 20 sites in the U.S. in COVER DFUs, which will compare treatment with SkinTE plus the standard-of-care to the standard-of-care alone.  The primary endpoint is the incidence of DFUs closed at 24 weeks.  Secondary endpoints include percent area reduction (PAR) at 4, 8, 12, 16, and 24 weeks, improved quality of life, and new onset of infection of the DFU being evaluated.  The Company expects enrollment to begin later in Q1 or in early Q2 and looks forward to providing updates as this study progresses and as PolarityTE engages FDA in discussions around the second pivotal study design and implementation.

FDA Guidance defines chronic cutaneous ulcers as those wounds that have “failed to proceed through an orderly and timely series of events to produce a durable structural, functional, and cosmetic closure,” and specifically include DFUs, venous leg ulcers and pressure injuries.  With respect to DFUs alone, the annual cost to the U.S. health care system ranges between $9 Billion and $13 Billion.  The five-year mortality and direct costs of care for people with DFU complications are comparable to cancer.



PolarityTE Investor Relations
(385) 831-5284

David Schull or Ignacio Guerrero-Ros